Literature DB >> 21357691

Vipirinin, a coumarin-based HIV-1 Vpr inhibitor, interacts with a hydrophobic region of VPR.

Eugene Boon Beng Ong1, Nobumoto Watanabe, Akiko Saito, Yushi Futamura, Khaled Hussein Abd El Galil, Atsushi Koito, Nazalan Najimudin, Hiroyuki Osada.   

Abstract

The human immunodeficiency virus 1 (HIV-1) viral protein R (Vpr) is an accessory protein that has been shown to have multiple roles in HIV-1 pathogenesis. By screening chemical libraries in the RIKEN Natural Products Depository, we identified a 3-phenyl coumarin-based compound that inhibited the cell cycle arrest activity of Vpr in yeast and Vpr-dependent viral infection of human macrophages. We determined its minimal pharmacophore through a structure-activity relationship study and produced more potent derivatives. We detected direct binding, and by assaying a panel of Vpr mutants, we found the hydrophobic region about residues Glu-25 and Gln-65 to be potentially involved in the binding of the inhibitor. Our findings exposed a targeting site on Vpr and delineated a convenient approach to explore other targeting sites on the protein using small molecule inhibitors as bioprobes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357691      PMCID: PMC3077605          DOI: 10.1074/jbc.M110.185397

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  HIV-1 Vpr induces the K48-linked polyubiquitination and proteasomal degradation of target cellular proteins to activate ATR and promote G2 arrest.

Authors:  Jean-Philippe Belzile; Jonathan Richard; Nicole Rougeau; Yong Xiao; Eric A Cohen
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

Review 2.  Vpr-host interactions during HIV-1 viral life cycle.

Authors:  Richard Y Zhao; Ge Li; Michael I Bukrinsky
Journal:  J Neuroimmune Pharmacol       Date:  2011-02-12       Impact factor: 4.147

3.  Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat.

Authors:  L Wang; S Mukherjee; F Jia; O Narayan; L J Zhao
Journal:  J Biol Chem       Date:  1995-10-27       Impact factor: 5.157

4.  Structure-functional analysis of human immunodeficiency virus type 1 (HIV-1) Vpr: role of leucine residues on Vpr-mediated transactivation and virus replication.

Authors:  Dineshkumar Thotala; Elizabeth A Schafer; Parithosh K Tungaturthi; Biswanath Majumder; Michelle L Janket; Marc Wagner; Alagarsamy Srinivasan; Simon Watkins; Velpandi Ayyavoo
Journal:  Virology       Date:  2004-10-10       Impact factor: 3.616

5.  The identification of an osteoclastogenesis inhibitor through the inhibition of glyoxalase I.

Authors:  Makoto Kawatani; Hideo Okumura; Kaori Honda; Naoki Kanoh; Makoto Muroi; Naoshi Dohmae; Masamichi Takami; Mitsuhiro Kitagawa; Yushi Futamura; Masaya Imoto; Hiroyuki Osada
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-11       Impact factor: 11.205

6.  Direct binding to nucleic acids by Vpr of human immunodeficiency virus type 1.

Authors:  S Zhang; D Pointer; G Singer; Y Feng; K Park; L J Zhao
Journal:  Gene       Date:  1998-06-08       Impact factor: 3.688

7.  Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases.

Authors:  Yong Xiao; Gang Chen; Jonathan Richard; Nicole Rougeau; Hongshan Li; Nabil G Seidah; Eric A Cohen
Journal:  Virology       Date:  2007-12-03       Impact factor: 3.616

8.  Direct Vpr-Vpr interaction in cells monitored by two photon fluorescence correlation spectroscopy and fluorescence lifetime imaging.

Authors:  Joëlle V Fritz; Pascal Didier; Jean-Pierre Clamme; Emmanuel Schaub; Delphine Muriaux; Charlotte Cabanne; Nelly Morellet; Serge Bouaziz; Jean-Luc Darlix; Yves Mély; Hugues de Rocquigny
Journal:  Retrovirology       Date:  2008-09-22       Impact factor: 4.602

9.  HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase.

Authors:  Jean-Philippe Belzile; Ghislaine Duisit; Nicole Rougeau; Johanne Mercier; Andrés Finzi; Eric A Cohen
Journal:  PLoS Pathog       Date:  2007-07       Impact factor: 6.823

10.  Trifluoromethyl ethers--synthesis and properties of an unusual substituent.

Authors:  Frédéric R Leroux; Baptiste Manteau; Jean-Pierre Vors; Sergiy Pazenok
Journal:  Beilstein J Org Chem       Date:  2008-04-29       Impact factor: 2.883

View more
  18 in total

1.  Bioactive Compounds from Medicinal Plants in Myanmar.

Authors:  Nwet Nwet Win; Hiroyuki Morita
Journal:  Prog Chem Org Nat Prod       Date:  2021

Review 2.  Alkynoates as Versatile and Powerful Chemical Tools for the Rapid Assembly of Diverse Heterocycles under Transition-Metal Catalysis: Recent Developments and Challenges.

Authors:  Imtiaz Khan; Aliya Ibrar; Sumera Zaib
Journal:  Top Curr Chem (Cham)       Date:  2021-01-05

3.  A Novel Class of HIV-1 Inhibitors Targeting the Vpr-Induced G2-Arrest in Macrophages by New Yeast- and Cell-Based High-Throughput Screening.

Authors:  Hirotaka Sato; Tomoyuki Murakami; Ryosuke Matsuura; Masako Abe; Seiji Matsuoka; Yoko Yashiroda; Minoru Yoshida; Hirofumi Akari; Yosuke Nagasawa; Masami Takei; Yoko Aida
Journal:  Viruses       Date:  2022-06-16       Impact factor: 5.818

4.  Targeting Tumor Associated Carbonic Anhydrases IX and XII: Highly Isozyme Selective Coumarin and Psoralen Inhibitors.

Authors:  Claudia Melis; Simona Distinto; Giulia Bianco; Rita Meleddu; Filippo Cottiglia; Benedetta Fois; Domenico Taverna; Rossella Angius; Stefano Alcaro; Francesco Ortuso; Marco Gaspari; Andrea Angeli; Sonia Del Prete; Clemente Capasso; Claudiu T Supuran; Elias Maccioni
Journal:  ACS Med Chem Lett       Date:  2018-06-06       Impact factor: 4.345

5.  Esculin and its oligomer fractions inhibit adhesion and migration of U87 glioblastoma cells and in vitro angiogenesis.

Authors:  Imen Mokdad-Bzeouich; Hervé Kovacic; Kamel Ghedira; Latifa Chebil; Mohamed Ghoul; Leila Chekir-Ghedira; José Luis
Journal:  Tumour Biol       Date:  2015-10-12

6.  Antiviral Ability of Kalanchoe gracilis Leaf Extract against Enterovirus 71 and Coxsackievirus A16.

Authors:  Ching-Ying Wang; Shun-Chueh Huang; Yongjun Zhang; Zhen-Rung Lai; Szu-Hao Kung; Yuan-Shiun Chang; Cheng-Wen Lin
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-15       Impact factor: 2.629

7.  Identification of a novel type of small molecule inhibitor against HIV-1.

Authors:  Byung Soo Kim; Jung Ae Park; Min-Jung Kim; Seon Hee Kim; Kyung Lee Yu; Ji Chang You
Journal:  BMB Rep       Date:  2015-02       Impact factor: 4.778

8.  A Coumarin-Based Analogue of Thiacetazone as Dual Covalent Inhibitor and Potential Fluorescent Label of HadA in Mycobacterium tuberculosis.

Authors:  Asma Farjallah; Laurent R Chiarelli; Martin Forbak; Giulia Degiacomi; Mathieu Danel; Fernanda Goncalves; Chantal Carayon; Cendrine Seguin; Marco Fumagalli; Monika Záhorszká; Elodie Vega; Souhir Abid; Anna Grzegorzewicz; Mary Jackson; Antonio Peixoto; Jana Korduláková; Maria Rosalia Pasca; Christian Lherbet; Stefan Chassaing
Journal:  ACS Infect Dis       Date:  2021-02-22       Impact factor: 5.084

9.  The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets.

Authors:  Tracy L Hartman; Robert W Buckheit
Journal:  Mol Biol Int       Date:  2012-07-10

10.  Development of a robust cell-based high-throughput screening assay to identify targets of HIV-1 viral protein R dimerization.

Authors:  Courtney Zych; Alexander Domling; Velpandi Ayyavoo
Journal:  Drug Des Devel Ther       Date:  2013-05-24       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.